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ABSTRACT
Adults with type 1 diabetes mellitus (T1DM) are at risk of premature osteoporosis and fractures. The onset of T1DM typically starts during
childhood and adolescence. Thus, the effects of DM on the skeleton may be established during this period. Studies in children with T1DM
primarily use DXAwith conflicting results. We present the first study in adolescents assessing the impact of T1DMon skeletalmicrostructure
and strength using HRpQCT. We recruited 22 patients aged 12 to 16 years with T1DM who were matched by age, gender, and pubertal
stagewith healthy controls. Paired t testswere applied to assess differences in cortical and trabecularmicroarchitecturemeasurements from
HRpQCT, and skeletal strength from HRpQCT-derived microfinite element analysis. Subtotal body, lumbar, and pelvic parameters were
assessed using DXA. There was no significant difference in subtotal body, lumbar spine, and pelvic BMD between T1DM and control pairs.
However, tibial trabecular thickness was lower (−0.005 mm; 95% CI, −0.01 to −0.001; p = 0.029) and trabecular loading was lower at the
distal radius (ratio of the load taken by the trabecular bone in relation to the total load at the distal end (Tb.F/TF) distal: −6.2; 95% CI,
−12.4 to −0.03; p = 0.049), and distal and proximal tibia (Tb.F/TF distal: −5.2, 95% CI, −9.2 to −1.2; p = 0.013; and Tb.F/TF proximal: −5.0,
95% CI, −9.8 to −0.1; p = 0.047) in T1DM patients. A subanalysis of radial data of participants with duration of T1DM of at least 2 years
and their matched controls demonstrated a reduced trabecular bone number (−0.15, 95% CI, −0.26 to −0.04; p = 0.012), increased trabec-
ular separation (0.041 mm, 95% CI, 0.009–0.072; p = 0.015), an increased trabecular inhomogeneity (0.018, 95% CI, 0.003–0.034; p = 0.021).
Regression models demonstrated a reduction in tibial stiffness (−0.877 kN/mm; p = 0.03) and tibial failure load (−0.044 kN; p = 0.03) with
higher HbA1C. Thus, in adolescents with T1DM, detrimental changes are seen in tibial and radial microarchitecture and tibial and radial
strength before changes in DXA occur and may result from poor diabetic control. © 2020 The Authors. JBMR Plus published by Wiley Peri-
odicals LLC on behalf of American Society for Bone and Mineral Research.
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Introduction
A dults with type 1 diabetes mellitus (T1DM) have anincreased risk of osteoporosis and fractures.(1–3) The pooled
relative risk for any fracture is 3.16;(4) the risk of hip fractures is
between 3.78 to 6.94 times higher than the normal adult popula-
tion.(1,5) Previous studies have shown that adults with T1DM
have reduced BMD,(1–3,6) and fracture risk is compounded by
poor diabetic control or coexistent diabetic complications.(3,7,8)
Theonset of T1DM is typically in childhood, with the peak age of
onset between 10 to 14 years,(1) leading to a long exposure to the
effects of hyperglycemia and hypoinsulinism. Significant bone
growth and remodeling occurs in childhood and adolescence with
25% of peak bone mass attained in adolescence.(9,10) Optimizing
peak bone mass in childhood and adolescence reduces fracture
risk.(10) It is thus plausible that the impact of T1DM on skeletal
health begins from diagnosis in childhood and adolescence, lead-
ing to skeletal changes and inadequate bone mass accrual. This
may subsequently lead to an increased risk of osteoporosis and
fractures in adults with T1DM.(7)
One of the earliest studies looking at the impact of T1DM on
skeletal health in children dates back to 1948 where a loss of
bone “content” was demonstrated through evaluation of con-
ventional X-rays.(11) Since then, there have been multiple studies
looking at DXA-derived BMD in children with T1DMwith conflict-
ing results; some showing reduced BMD,(4,6,10,11) and others
showing no difference in BMD compared with controls.(12–14)
The inconsistencies in BMD seen between studies of children
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with T1DM may be related to the age of the patient, time from
diagnosis, and diabetic control. Despite this, studies showing
no reduction in BMD have shown changes in the bone markers
such as osteocalcin, PINP, and urinary pyridinoline and deoxypyr-
idinoline, reflecting lower bone formation and an increased bone
turnover.(14,15) Changes in bone markers can be seen within a
year of onset of T1DM, suggesting that skeletal alterations may
be taking place at a microarchitectural level.(9) BMD may also
be considered an inadequate predictor of fracture risk in DM. In
a previous meta-analysis,(1) lower BMD was demonstrated in
adults with T1DM, but higher BMD in adults with T2DM. Yet an
increased fracture risk was observed in both conditions. More-
over, the fracture risk in T1DM is also higher than the calculated
risk if it is solely based on BMD. Patients with T1DM can also still
develop fractures even with a normal BMD, suggesting that frac-
ture risk may also be driven by more subtle detrimental micro-
structural skeletal alterations.(15)
Changes in bone microarchitecture that influence bone qual-
ity and strength may precede observable changes in DXA-
derived bone mass in children. Comparable studies using pQCT
in children have demonstrated detrimental changes in the corti-
cal compartment in children and adolescents with T1DM.(16, 17) In
participants with T1DM, Bechtold and colleagues demonstrated
a reduction in total and cortical cross-sectional area in prepuber-
tal participants and reduction in total cross-sectional area in par-
ticipants in early puberty at the radius comparedwith the normal
reference.(16) Saha and colleagues showed reduced bone cross-
sectional size, and reduced cortical BMD and cross-sectional area
in adolescents with T1DM compared with healthy controls.(17)
However, pQCT provides limited information about the cortical
and trabecular microarchitecture, and does not provide proxies
of bone strength calculated using finite element analysis.
HRpQCT was therefore used in this study as it provides high-
resolution images of the cortical and trabecular microarchitec-
ture to a resolution of 82 micrometers and estimated bone
strength parameters.(18,19)
We hypothesized that detrimental changes in bone mass and
the cortical and trabecular bone microarchitecture, and proxies
in bone strength will be seen in adolescents with T1DM com-
pared with healthy controls. Thus our objectives were to deter-
mine: (i) whether T1DM causes changes in cortical and
trabecular bone microarchitecture and proxies of bone strength
in adolescents; (ii) if T1DM causes changes in subtotal body, lum-
bar spine, and pelvic bone mass; and (iii) if glycemic control
and/or duration of diabetes has an impact on cortical and trabec-
ular bonemicroarchitecture and proxies of bone strength in ado-
lescents with T1DM.
Participants and Methods
This study was approved by the South Yorkshire Research Ethics
Committee. All investigations were carried out in accordance
with the ethical standards laid down in the 1964 Declaration of
Helsinki and its later amendments and in accordance with the
International Conference on Harmonization Good Clinical Prac-
tice guidelines. All participants gave fully informed written con-
sent prior to their participation.
Adolescents from a white population aged 12 to 16 years with
T1DM were recruited from pediatric outpatient diabetes clinic at
Sheffield Children’s Hospital, UK. Control participants were
recruited via advertisements through emails, social media, and
as siblings of participants with T1DM. Recruitment took place
between October 2016 and April 2018. Adolescents with an
active malabsorption condition, metabolic bone disease, renal
disease, immobilization of greater than 3 months, a known skel-
etal disorder, a fracture history within 12 months of consent, an
active eating disorder, or who were on medications that can
affect bone metabolism were excluded from the study. Fracture
history was assessed in both groups. The medical notes of
patients with T1DM were reviewed to determine age of diagno-
sis, duration of T1DM, and to obtain average HbA1C over the
1 year prior to the study. As the study involved exposure to radi-
ation, female participants underwent a urine pregnancy test.
Anthropometry was undertaken with subjects wearing light
clothing. Height was measured using a portable stadiometer
(SECA 214 portable stadiometer, Birmingham, UK) to the nearest
1 mm and weight to the nearest 0.1 kg using electronic balance
scales (SECA 770 digital weighing scales). BMI was calculated as
weight (kg)/height2 (m2). Pubertal assessment was conducted
using Tanner stage self-assessment cards. Total body less head,
lumbar spine, and pelvis BMD (BMD – g/cm2); bone mineral con-
tent (BMC – g); bone area (BA – cm2); and fat and leanmass (total
and percentage) were measured using the Discover A densitom-
eter (Hologic Inc., Bedford, MA, USA). Device stability was moni-
tored using an anthropomorphic spine phantom, and weekly
scans of the standard quality control (European Spine Phantom;
QRM—Quality Assurance in Radiology and Medicine, Moehren-
dorf, Germany) were also performed using the manufacturer’s
software.
HRpQCT was performed on the nondominant, nonfractured
limb (Fig. 1). The image acquisition and analysis of a 9-mm–
defined section of the ultradistal radius and tibia scanned was
performed using the standard built-in software (XtremeCT, ver-
sion 6.0, Scanco Medical AG, Brüttisellen, Switzerland). The scan-
ning methodology has previously been described.(18,19) In all
postpubertal participants with fused tibial and radial growth
plates, a reference line was placed on the scan image at the end-
plate of the distal tibia and on the notch on the articular surface
of the distal radius to indicate the position of the first measure-
ment slice (22.5 and 9.5 mm proximal from the reference line
for the tibia and radius, respectively). In prepubertal participants
and in those participants with open tibial and radial growth
plates, the reference line was placed on the scan image at the
proximal end of the growth plate to indicate the position of
the first measurement slice (1 mm proximal from the reference
line). A single stack of parallel CT slices (110 slices = 9.02 mm)
for each site was acquired in the high-resolution mode (image
matrix = 1536 × 1536). Daily measurements of the manufacturer
device-specific phantom (Scanco Medical AG) were performed
to monitor the stability of the XtremeCT. Assessment of bone
strength was determined using microfinite element analysis
(mFEA), inbuilt software on HRpQCT.
HRpQCT densitometric measurements included total density
(mg/cm3), trabecular density (mg/cm3), and cortical density
(mg/cm3). Measures of microarchitectural properties included
trabecular number (1/mm), trabecular thickness (mm), trabecu-
lar separation (mm), bone volume fraction (%), endosteal and
periosteal perimeter (mm) and cortical thickness (mm). Extended
cortical analysis techniques were applied to the segmented
scans using specialist software provided by Scanco Medical AG
(version 6) and following the approaches described by Burghardt
and colleagues(20), Engelke and colleagues,(21) and Nishiyama
and colleagues(22) to assess cortical porosity (%) and mean corti-
cal pore diameter (μm). Measures of bone strength were deter-
mined by mFEA using software developed by Scanco Medical
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Fig 1. Tibial and radial imagesobtained fromHRpQCT foraparticipantwith type1diabetesmellitus (A) andanage-, pubertal stage-, andgender-matchedcontrol (B).
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AG (version 1.13; FE-solver included in the image processing lan-
guage). Analysis variables included bone stiffness (kN/mm), esti-
mated ultimate failure load (kN), the ratio of the load taken by
the trabecular bone in relation to the total load at the distal
end (%) and proximal end (%), and average von Mises stresses
in the trabecular (MPa) and the cortical (MPa) bone.
Participants with T1DM were matched to controls according
to gender, age, and pubertal status. Comparisons between
groups for age, anthropometry, and bone parameters (DXA,
HRpQCT, and mFEA) were made using paired t-tests. Paired dif-
ferences in bone parameters are presented as unadjusted data
and data adjusted for height and weight using mixed effects lin-
ear model with pair as random intercept. Linear regression anal-
ysis was used to determine impact of glycemic control
(as assessed by average HbA1c) and duration of T1DMDM on
the skeletal parameters as assessed by HRpQCT with age and
gender included in the model as independent variables. Signifi-
cance was determined at a p value of ≤0.05. The analysis was
done using the R Project for Statistical Computing.(23)
Results
From the adolescents contacted through the pediatric outpa-
tient diabetic clinics, 29 adolescents with T1DM were eligible
and consented to be part of the study. From these, 22 adoles-
cents participated in the study. Thirty healthy controls were con-
tacted and 25 adolescents participated in the study. Data from
three healthy controls were excluded from the study because
they could not be matched to the existing participants with
T1DM (three male participants).
Twenty-two participants with T1DM were age-, pubertal stage-,
and gender-matched with healthy controls. At the time of analysis,
HRpQCT data could not be obtained from two participants with
T1DM (because of movement artifacts); hence, analyses of these
data were from 40 participants (20 matched pairs). DXA data were
obtained from all participants (22matched pairs). Demographics of
the cohort are presented in Table 1. Therewere 13 femalematched
pairs (n = 26) in this study. Participants with T1DM were signifi-
cantly heavier (8.3 kg = paired difference and 95% CI is 2.9–13.8,
p = 0.005) and had a higher BMI (3.0 is the paired difference with
95% CI 1.0–5.1, p = 0.006) than controls.
Eight participants with T1DM previously had fractures; six par-
ticipants sustained one fracture, and two participants had two
previous fractures. Ten healthy controls previously had fractures;
seven participants had sustained one fracture and three partici-
pants had two fractures.
Among the participants with T1DM, the average age of onset
of diagnosis was 9.25  1.62 years. The duration of DM among
participants ranged from 2 months (participant was 13.1 years
at time of study) to 14.5 years (participant was 15.5 years at time
of study). The average HbA1C was 62.4  5.38 mmol (excluding
one participant who did not have a HbA1C measurement as the
duration of DM was <3 months).
There were no significant differences in BA, BMC, and BMD for
total body less head, lumbar spine, and pelvic sites between par-
ticipants with T1DM andmatched controls (Table 2). After adjust-
ing for differences in height and weight, there were no
significant differences in fat and lean mass between both
groups. A further subanalysis was done by excluding participants
with a short T1DM duration (<2 years) and their paired healthy
controls (Table 3), and there remained no difference in bone
densitometry parameters.
HRpQCT comparisons of the radius are presented in Table 4.
Participants with T1DM carried on average 6.2% less load at the
distal surface of the trabecular bone (95% CI, −12.4 to −0.03;
p = 0.049) compared with controls. However, when T1DM partic-
ipants of <2 years DM duration and their paired controls were
excluded in a further subanalysis (Table 5), further significant
changes in the trabecular bone were found. At the radius, partic-
ipants with T1DM had a reduced trabecular bone number by
0.15 (95% CI,−0.26 to−0.04; p = 0.012), increased trabecular sep-
aration by 0.041 mm (95% CI, 0.009–0.072; p = 0.015), an
increased trabecular inhomogeneity by 0.018 (95% CI,
0.003–0.034; p = 0.021) and carried 9.7% less load at the distal
surface of the trabecular bone (95% CI, −17.3 to −2.1;
p = 0.017) compared with controls.
HRpQCT analyses of the tibia are presented in Table 6. Partic-
ipants with T1DM had a lower mean trabecular thickness
(−0.005 mm; 95% CI, −0.01 to −0.001; p = 0.029) and had a
5.2% mean reduction in load (95% CI, −9.2 to −1.2; p = 0.013)
on the distal surface and 5.0% decreased load (95% CI, −9.8 to
−0.1; p = 0.047) on the proximal surface of the tibial trabecular
bone compared with controls. When T1DM participants of
<2 years DM duration and their paired controls were excluded
in a further subanalysis (Table 7), lower trabecular thickness
remained a consistent finding in children with T1DM
(−0.007 mm; 95%CI,−0.013 to−0.001; p = 0.029) comparedwith
controls; however, changes in load carried by the trabecular
bone were no longer significant.
Linear regression analysis was used to determine the relationship
betweenHbA1C anddurationof T1DMDMon skeletal parameters as
assessed by HRpQCT. The regression models were adjusted for age
and gender because this analysis was only performed for the group
of T1DMpatients. Therewas no correlation betweenHbA1Cor dura-
tion of T1DMDM and radial skeletal parameters once adjusted for
age and gender. In contrast, an increase in one unit of HbA1C was
associated with a reduction in the estimated failure load by 0.044
Table 1. Comparison of Anthropometry in T1DM and Control Groups andMean Difference (95% CI) Matched by Age, Gender, and Puber-
tal Stage
T1DM Control Paired difference (T1DM – control)
Mean SD Mean SD Mean (95% CI) p Value
Age (years) 13.8 1.2 13.6 1.2 0.1 (−0.03 to 0.24) 0.130
Tanner stage 3.4 0.9 2.9 1.2 0.5 (−0.1 to 1.0) 0.091
Height (cm) 160.6 9.4 159.7 10.2 0.9 (−3.9 to 5.8) 0.693
Weight (kg) 58.1 14.6 49.8 10.2 8.3 (2.9 to 13.8) 0.005
BMI 22.4 4.4 19.3 2.5 3.0 (1.0 to 5.1) 0.006
Significance is reached at p ≤ 0.05. T1DM = type 1 diabetes mellitus.
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Table 2. Comparison of DXA Data for Total Body Less Head, Lumbar Spine, and Pelvis in T1DM and Control Groups and Mean Difference (95% CI) Matched by Age, Gender, and Pubertal
Stage
N
T1DM Control Paired differencea (T1DM – control) Paired differenceb (T1DM – control)
Mean SD Mean SD Mean (95% CI) p Value Mean (95% CI) p Value
Subtotal body area (cm2) 22 1570.1 203.3 1533.5 213.8 36.6 (−64.4 to 137.6) 0.459 −53.6 (−119.0 to 11.8) 0.103
Subtotal body BMC (g) 22 1328.5 235.7 1308.4 298.3 20.1 (−124.6 to 164.7) 0.776 −89.0 (−186.9 to 8.8) 0.072
Subtotal body BMD (g/cm2) 22 0.841 0.049 0.844 0.089 −0.002 (−0.048 to 0.043) 0.913 −0.024 (−0.062 to 0.014) 0.209
Lumbar spine area (cm2) 22 45.9 6.9 45.6 8.6 0.3 (−4.9 to 5.4) 0.918 −1.3 (−5.9 to 3.4) 0.579
Lumbar spine BMC (g) 22 40.7 9.8 40.7 12.2 −0.1 (−6.4 to 6.3) 0.980 −2.4 (−8.8 to 3.9) 0.438
Lumbar spine BMD (g/cm2) 22 0.879 0.125 0.880 0.144 −0.001 (−0.064 to 0.063) 0.983 −0.027 (−0.098 to 0.043) 0.425
Pelvic area (cm2) 22 189.6 28.6 192.5 39.4 −2.9 (−23.0 to 17.1) 0.763 −11.5 (−29.7 to 6.6) 0.200
Pelvic BMC (g) 22 208.6 47.1 207.4 62.4 1.2 (−29.3 to 31.8) 0.934 −17.9 (−43.7 to 8.0) 0.164
Pelvic BMD (g/cm2) 22 1.094 0.140 1.059 0.140 0.034 (−0.048 to 0.116) 0.393 −0.017 (−0.090 to 0.057) 0.637
Whole-body fat (g) 22 16842.0 7360.9 12552.5 4378.8 4289.6 (1221.7–7357.5) 0.008 350.6 (−1734.1 to 2435.3) 0.729
Whole-body lean (g) 22 41513.3 8325.9 37276.4 7729.6 4236.9 (419.2–8054.7) 0.031 −178.0 (−2279.5 to 1923.5) 0.861
Whole-body percentage fat (%) 22 27.7 7.1 25.0 6.2 2.8 (−1.3 to 6.9) 0.175 −0.2 (−4.1 to 3.8) 0.932
Significance is reached at p ≤ 0.05. T1DM = type 1 diabetes mellitus.
aUnadjusted analysis using paired samples t test.
bAdjusted for height and weight using mixed effects linear model with pair as random intercept.
Table 3. Comparison of DXA Data for Total Body Less Head, Lumbar Spine, and Pelvis in T1DM and Control Groups and Mean Difference (95% CI) Matched by Age, Gender, and Pubertal
Stage After Participants With T1DM <2 years and the Paired Controls Were Excluded
N
T1DM Control Paired differencea (T1DM – control) Paired differenceb (T1DM – control)
Mean SD Mean SD Mean (95% CI) p Value Mean (95% CI) p Value
Subtotal body Area (cm2) 14 1607.1 193.9 1521.9 233.5 85.2 (−58.0 to 228.4) 0.221 −57.4 (−153.5 to 38.7) 0.215
Subtotal body BMC (g) 14 1367.9 240.2 1300.9 334.5 67.0 (−151.8 to 285.8) 0.520 −112.5 (−266.3 to 41.3) 0.136
Subtotal body BMD (g/cm2) 14 0.846 0053 0.843 0.104 0.003 (−0.068 to 0.075) 0.919 −0.033 (−0.094 to 0.027) 0.253
Lumbar spine Area (cm2) 14 45.8 6.7 46.5 8.5 −0.6 (−7.1 to 5.9) 0.842 −3.9 (−9.9 to 2.2) 0.191
Lumbar spine BMC (g) 14 41.9 10.0 41.5 12.6 0.3 (−8.4 to 9.1) 0.932 −3.9 (−13.1 to 5.2) 0.365
Lumbar spine BMD (g/cm2) 14 0.907 0.139 0.881 0.161 0.025 (−0.073 to 0.123) 0.586 −0.017 (−0.134 to 0.099) 0.752
Pelvic area (cm2) 14 196.9 22.8 191.6 44.9 5.3 (−21.9 to 32.5) 0.679 −10.8 (−37.3 to 15.7) 0.390
Pelvic BMC (g) 14 220.3 47.0 207.6 70.6 12.7 (−31.5 to 57.0) 0.545 −20.7 (−60.5 to 19.2) 0.279
Pelvic BMD (g/cm2) 14 1.112 0.160 1.062 0.159 0.051 (−0.075 to 0.176) 0.399 −0.034 (−0.150 to 0.083) 0.538
Whole-body fat (g) 14 18053.5 7892.9 11701.98 4528.6 6351.5 (2285.8–10417.2) 0.005 1178.3 (−2124.0 to 4480.6) 0.449
Whole-body lean (g) 14 42833.6 9367.3 36803.3 9159.2 6030.3 (438.6– 11,622.0) 0.037 −984.0 (−4313.4 to 2345.4) 0.529
Whole-body percentage fat (%) 14 28.6 7.2 24.0 6.9 4.6 (−1.0 to 10.2) 0.101 1.5 (−4.6 to 7.7) 0.595
Significance is reached at p ≤ 0.05. N = Number of matched pairs; T1DM = type 1 diabetes mellitus.
aUnadjusted analysis using paired samples t test.
bAdjusted for height and weight using mixed effects linear model with pair as random intercept.
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kN (95%CI,−0.083 to−0.006; p= 0.035) at the distal tibia. This differ-
ence remained significant after adjusting for age and gender
(−0.045 kN; 95% CI, −0.086 to −0.003; p = 0.039). A reduction of
0.877 kN/mm of tibial stiffness was also associated with each unit
increase in HbA1C (95% CI, −1.684 to −0.07; p = 0.035) and again
remained significant after adjusting for age and gender
(−0.923 kN/mm; 95% CI, −1.783 to −0.062; p = 0.037). There was
no correlation between duration of DM and tibial skeletal parame-
ters once adjusted for age and gender.
Discussion
We hypothesized that changes in bone microarchitecture and
strength occur in adolescents with T1DM, and these changes
precede changes in DXA-derived bone parameters.
In our study, we compared adolescents with T1DM with age-,
sex-, and pubertal stage-matched controls, thus accounting for
differences in physiological maturity at the same age. We did
not observe differences in BA, BMC, and BMD at the total body
(less head), lumbar spine, and pelvic sites. Our results thus sup-
port other studies that have shown no differences in total body
and regional BMD in patients with T1DM compared with healthy
controls.(12–14) However, in contrast, some studies have shown a
reduction in BMD.(4,8–10) Inconsistencies between studies using
DXA are related to the age of the population and the challenges
with using areal bone density to assess bone mass and fracture
risk, which inherently under- and overestimate bone mass in
smaller and taller children, respectively.
To our knowledge, this is the first study using HRpQCT to look
at skeletal microarchitecture in adolescents with T1DM. HRpQCT
provides high-resolution in vivo bone biopsy, giving insight into
the microarchitectural parameters and integrity of cortical and
trabecular compartments.(18,19) Moreover, HRpQCT provides rel-
evant information about skeletal integrity and strength, albeit
at the distal appendicular skeleton. We provide evidence for
reduced bone strength at the distal radius and tibia of adoles-
cents with T1DM, demonstrating a 6.2% mean reduction in
load-bearing at the distal surface of trabecular bone in the radius
and 5.2% and 5.0% mean reduction in load-bearing on the distal
and proximal surface of tibial trabecular bone respectively, com-
pared with healthy controls. Following subanalysis in children
who had T1DM for >2 years, the reduction in load-bearing at
the distal surface of tibial trabecular load in the T1DM group
was no longer present. Conversely, in the same subanalysis, a
reduced trabecular bone number, increased trabecular separa-
tion, and increased trabecular inhomogeneity was observed at
the radius with a 9.7% reduction in the trabecular load at the dis-
tal radius. Thus, those with a duration of T1DM >2 years demon-
strated an alteration in trabecular microarchitecture that could
translate into a reduction in radial strength. However, given the
lack of normative data on individual HRpQCT mFe parameters,
it is difficult to determine whether the identified 9.7% reduction
in trabecular load at the distal radius in our T1DM cohort is
Table 4. Comparison of HRpQCT Cortical, Trabecular, and mFEA Radial Parameters and Mean Difference Between T1DM and Control
Groups Matched for Age, Pubertal Stage, and Gender Calculated by Paired t Tests (95% CI)
Radial HRpQCT parameters N
T1DM Control
Paired difference (T1DM –
control)
Mean SD Mean SD Mean (95% CI)
p
Value
Total bone area (cm3) 20 251.7 45.6 267.3 55.9 −15.6 (−46.3 to 15.2) 0.303
Volumetric bone density (mg/cm3) 20 248.5 41.4 252.0 50.8 −3.6 (−37.8 to 30.7) 0.830
Cortical bone area (cm3) 20 27.0 12.0 24.3 12.9 2.7 (−5.7 to 11.2) 0.504
Cortical bone density (mg/cm3) 20 669.9 83.2 643.3 65.1 26.6 (−15.4 to 68.5) 0.201
Cortical bone thickness (mm) 20 0.424 0.196 0.396 0.241 0.029 (−0.121 to 0.178) 0.695
Cortical bone perimeter (mm) 20 64.7 6.6 66.4 7.6 −1.7 (−5.7 to 2.3) 0.394
Cortical porosity 20 0.036 0.018 0.043 0.019 −0.007 (−0.018 to 0.005) 0.248
Periosteal perimeter (mm) 20 67.1 7.6 69.1 8.7 −2.0 (−6.6 to 2.6) 0.379
Endosteal perimeter (mm) 20 60.3 7.2 63.3 8.5 −3.0 (−7.6 to 1.5) 0.182
Trabecular bone area (cm3) 20 213.3 45.1 230.0 52.5 −16.6 (−46.9 to 13.6) 0.265
Trabecular bone density (mg/cm3) 20 167.0 32.6 186.2 38.2 −19.2 (−44.4 to 6.0) 0.127
Trabecular BV/TV 19 0.140 0.027 0.157 0.032 −0.017 (−0.039 to 0.005) 0.131
Trabecular bone number (1/mm) 20 2.14 0.23 2.21 0.17 −0.07 (−0.18 to 0.04) 0.196
Trabecular thickness (mm) 20 0.065 0.009 0.070 0.012 −0.005 (−0.014 to 0.003) 0.203
Trabecular separation (mm) 20 0.409 0.057 0.387 0.041 0.022 (−0.004 to 0.048) 0.090
Trabecular inhomogeneity 20 0.159 0.029 0.151 0.023 0.009 (−0.006 to 0.023) 0.222
Stiffness (kN/mm) 20 71.3 44.5 67.2 19.9 4.2 (−20.4 to 28.7) 0.728
Estimated failure load (kN) 20 3.58 1.85 3.46 0.95 0.12 (−0.94 to 1.18) 0.815
(Tb.F/TF) distal (percentage of load carried by
trabecular bone at distal surface
20 59.2 12.6 65.4 6.3 −6.2 (−12.4 to −0.03) 0.049
(Tb.F/TF) proximal (percentage of load carried by
trabecular bone at proximal surface)
20 30.3 13.5 34.3 7.2 −4.0 (−10.8 to 2.7) 0.229
Trabecular Von Mises stress (MPa) 20 5.22 1.04 5.43 0.74 −0.22 (−0.92 to 0.49) 0.534
Cortical Von Mises stress (MPa) 20 8.24 0.36 8.17 0.34 0.07 (−0.14 to 0.28) 0.510
Significance is reached at p ≤ 0.05.
BV/TV = bone volume fraction; N = number of matched pairs; mFEA = microfinite element analysis; T1DM = type 1 diabetes mellitus; Tb.F/TF = _______.
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physiologically significant.(24,25) T1DM may have a more pro-
found impact on the radius and thus, nonload-bearing bone
and this finding may in part explain the increased fracture risk
observed in adults with T1DM. Moreover, radial and tibial trabec-
ular and bone area were lower in children with T1DM, although
these differences were not significant in the analysis.
Alterations in the bone microarchitecture and loading proper-
ties of the bone were thus identified in adolescents with T1DM
despite no observable change in total body or regional BMD.
We speculate that the consistently observed reduction in bone
mass and increased fracture risk observed in adults with T1DM
may be preceded and explained by more subtle skeletal micro-
architectural changes in childhood. Previously observed alter-
ations in bone turnover markers in children with T1DM, despite
no significant differences in bone density, appear to support this
finding, and with our data collectively suggest that the decline in
skeletal quality in children with T1DM may begin in
childhood.(14,15,26)
To ensure that the significant changes in bone parameters
identified between the two groups were not caused by changes
in body composition, we assessed the impact of whole-body fat
mass and leanmass on HRpQCT andmFEA parameters that were
significantly different between the two groups to determine the
effect of body composition on these differences (data not
included). We analyzed the effect of an increase per 100 grams
of fat and lean mass and an increase in 1% fat mass and lean
mass on each of the parameters for the diabetic group, and then
adjusted the data for age and sex. Moreover, we performed a
sensitivity analysis to ensure outliers did not skew the results.
We found that in children with T1DM, whole-body fat mass, per-
centage fat mass, and percentage lean mass were positively cor-
related with trabecular thickness at the radius following
adjustment for age and sex. Further, an increase in percentage
fat mass was also correlated with an increase in trabecular load
at the distal radius. Body composition was not correlated with
the relevant bone parameters at the tibia. In addition, as there
was no difference in fat and lean mass observed between our
cohorts, we surmise that the differences in bone parameters
observed between the two groups are unlikely to be caused by
changes in body composition in patients with T1DM.
In our study, at least at the tibia, a reduction in bone strength
may be related to glycemic control. This concurs with other stud-
ies showing the negative impact of poor glycemic control on
bone.(8,12,27–29) Our initial logistic regression analysis suggested
that the duration of DM may be related to changes in tibial
microarchitectural properties; however, this relationship disap-
peared after adjusting for age and gender. This is in agreement
with other studies.(12,29)
In adult patients with T1DM,(27) no differences in HRpQCT
parameters were identified between T1DM patients without
the presence of microvascular disease and healthy controls.
However, T1DM patients with established microvascular
changes showed lower total, trabecular, and cortical volumetric
BMD, thinner radial cortex, and lower total and trabecular vBMD
Table 5. Comparison of HRpQCT Cortical, Trabecular, and mFEA Radial Parameters and Mean Difference Between T1DM and Control
Groups (With T1DM Participants of DM Duration < 2 years and Paired Controls Excluded) Matched for Age, Pubertal Stage, and Gender
Calculated by Paired t Tests (95% CI)
Radial HRpQCT parameters N
T1DM Control Paired difference (T1DM – control)
Mean SD Mean SD Mean (95% CI) pValue
Total bone area (cm3) 13 250.8 42.8 272.1 61.7 −21.4 (−59.9 to 17.1) 0.250
Total bone density (mg/cm3) 13 242.9 46.6 256.3 59.0 −13.3 (−64.0 to 37.3) 0.577
Cortical bone area (cm3) 13 29.0 12.3 26.7 15.1 2.3 (−10.7 to 15.3) 0.711
Cortical bone density (mg/cm3) 13 679.8 76.9 650.2 72.8 29.6 (−26.8 to 86.1) 0.275
Cortical bone thickness (mm) 13 0.452 0.198 0.445 0.280 0.008 (−0.221 to 0.236) 0.943
Cortical bone perimeter (mm) 13 65.0 6.6 66.9 8.3 −1.9 (−6.9 to 3.2) 0.432
Cortical porosity 13 0.038 0.017 0.044 0.020 −0.006 (−0.020 to 0.008) 0.353
Trabecular bone area (cm3) 13 211.0 42.5 232.7 57.7 −21.7 (−59.5 to 16.1) 0.236
Trabecular bone density (mg/cm3) 13 155.7 26.3 187.1 45.2 −31.3 (−67.3 to 4.6) 0.082
Meta trabecular density (mg/cm3) 13 221.7 30.0 248.4 47.2 −26.8 (−64.0 to 10.4) 0.143
Inner trabecular density (mg/cm3) 13 110.1 27.3 144.7 45.7 −34.6 (−71.4 to 2.2) 0.063
Meta TB/inner TB 13 2.08 0.35 1.79 0.32 0.28 (−0.04 to 0.61) 0.081
Trabecular BV/TV 12 0.131 0.023 0.159 0.038 −0.028 (−0.061 to 0.005) 0.084
Trabecular bone number (1/mm) 13 2.06 0.20 2.21 0.20 −0.15 (−0.26 to −0.04) 0.012
Trabecular thickness (mm) 13 0.063 0.008 0.070 0.014 −0.007 (−0.020 to 0.005) 0.224
Trabecular separation (mm) 13 0.427 0.055 0.386 0.049 0.041 (0.009 to 0.072) 0.015
Trabecular inhomogeneity 13 0.170 0.026 0.151 0.026 0.018 (0.003 to 0.034) 0.021
Stiffness (kN/mm) 13 60.8 13.0 69.2 24.5 −8.5 (−28.8 to 11.9) 0.383
Estimated failure load (kN) 13 3.12 0.63 3.56 1.17 −0.43 (−1.40 to 0.54) 0.353
(Tb.F/TF)dist 13 54.6 9.7 64.3 7.0 −9.7 (−17.3 to −2.1) 0.017
(Tb.F/TF)prox 13 25.5 8.6 32.9 7.8 −7.4 (−15.1 to 0.3) 0.057
Trabecular Von Mises stress (MPa) 13 4.93 0.67 5.35 0.85 −0.43 (−1.29 to 0.44) 0.302
Cortical Von Mises stress (MPa) 13 8.22 0.36 8.14 0.36 0.08 (−0.19 to 0.36) 0.533
Periosteal perimeter (mm) 13 67.0 7.3 69.8 9.6 −2.8 (−8.4 to 2.7) 0.289
Endosteal perimeter (mm) 13 60.4 7.4 64.4 9.4 −3.9 (−10.1 to 2.2) 0.186
Significance is reached at p ≤ 0.05. BV/TV = bone volume fraction; N = number of matched pairs; mFEA = microfinite element analysis; T1DM = type 1 dia-
betes mellitus; TB = Meta TB/inner TB = meta-to-inner trabecular density; Tb.F/TF = ratio of the load taken by the trabecular bone in relation to the total load.
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at the tibia.(27) Despite this, no differences were observed in
bone strength. Differences in the microarchitectural findings
between adolescents and adults with T1DM, may in part relate
to the impact of T1DM during skeletal development. Adoles-
cence is a period of significant bone mass accrual and increased
bone strength.(30) Thus, the impact of T1DM may differ during
phases of skeletal development and maturity.
Multiple mechanisms by which T1DM may cause impaired
bone turnover and mineralization have been proposed.(31) Our
study showed that T1DM had a negative impact on the trabecu-
lar compartment at the radius and tibia, with others showing
deterioration in the cortical bone compartment.(16,17,27) Insulin
has an anabolic effect on bone by stimulating osteoblast differ-
entiation in the bone marrow; thus, reduction in insulin may
impair bone formation at a critical time of peak bone mass
accrual.(32,33) Adolescents with T1DM have lower osteocalcin
and insulin-like growth factor 1 levels, factors that are important
in skeletal development.(34) Production of advanced end glyco-
sylation products secondary to chronic hyperglycemia have also
been implicated in causing impaired bone formation.(35,36) T1DM
also may also impair osteocyte function through its impact on
sclerostin expression.(32,36,37)
Adolescents with T1DM were heavier and had a higher BMI
compared with the healthy controls in our study. This corre-
sponds with data from the National Pediatrics Diabetes Audit(38)
showing a trend for higher BMI in children with T1DM. It could be
postulated that the higher weight and BMI has led to skeletal
microarchitectural deterioration rather than T1DM, as obesity
has been associated with an increased risk of fractures and
change in skeletal microarchitecture in children.(39,40) However,
the mean BMI in our T1DM cohort was within the normal range
for age. Although obesity has been recognized as a risk factor
for fractures, increased fat mass that is not excessive could have
a positive impact on skeletal development.(40) There was also no
significant difference in fat and leanmass or percentage body fat
between T1DM participants and paired controls in our group
after adjustment for height and weight, and we further showed
that the differences in trabecular parameters between our
groups could not be explained by differences in fat or lean mass.
Therefore, the deterioration in bone microarchitecture seen in
our adolescents with T1DM cannot be explained by the higher
BMI alone.
There were several limitations to our study. This was a small
pilot study; thus, our ability to detect other differences in skeletal
microarchitecture and integrity between the groups was limited.
Studying a larger population of adolescents and children with
T1DM using HRpQCT could further define the relationship
between skeletal microarchitecture and duration of DM, age of
onset, and glycemic control. Although we detected no signifi-
cant differences in fat and lean mass between both groups and
we also corrected for height and weight to remove these mea-
sures as confounding factors, matching for BMI in addition to
age, gender, and pubertal stage would potentially preclude the
impact of body composition skeletal microarchitecture. We rec-
ognize that the measures of bone strength using finite element
analysis represent proxies of bone strength and cannot replace
Table 6. Comparison of HRpQCT Cortical, Trabecular, andmFEA Tibial Parameters Between T1DM and Control ChildrenMatched for Age,
Pubertal Stage, and Gender Calculated by Paired t Tests – Mean Difference (95% CI)
Tibial HRpQCT parameters N
T1DM Control Paired difference (T1DM – control)
Mean SD Mean SD Mean (95% CI)
p
Value
Total bone area (cm3) 20 838.5 175.3 906.0 147.9 −67.5 (−149.0 to 14.1) 0.100
Total bone density (mg/cm3) 20 240.5 45.7 237.3 33.1 3.2 (−20.1 to 26.6) 0.777
Cortical bone area (cm3) 20 58.2 43.9 47.1 29.3 11.1 (−4.8 to 27.1) 0.160
Cortical bone density (mg/cm3) 20 680.2 123.2 650.5 105.7 29.7 (−9.9 to 69.4) 0.133
Cortical bone thickness (mm) 20 0.550 0.451 0.413 0.292 0.137 (−0.022 to 0.295) 0.088
Cortical bone perimeter (mm) 20 114.3 13.8 119.3 11.3 −4.9 (−10.9 to 1.1) 0.101
Cortical porosity 20 0.045 0.021 0.048 0.019 −0.003 (−0.014 to 0.007) 0.473
Periosteal perimeter (mm) 20 120.6 19.2 125.8 16.0 −5.2 (−12.5 to 2.0) 0.146
Endosteal perimeter (mm) 20 108.7 14.1 114.0 12.0 −5.4 (−11.4 to 0.6) 0.077
Trabecular bone area (cm3) 20 761.1 195.1 836.4 155.6 −75.3 (−161.5 to 10.8) 0.083
Trabecular bone density (mg/cm3) 20 184.3 24.0 197.6 24.4 −13.3 (−28.9 to 2.2) 0.089
Trabecular BV/TV 20 0.154 0.020 0.165 0.020 −0.011 (−0.024 to 0.002) 0.088
Trabecular bone number (1/mm) 20 2.21 0.30 2.18 0.39 0.04 (−0.13 to 0.20) 0.649
Trabecular thickness (mm) 20 0.070 0.009 0.075 0.009 −0.005 (−0.010 to −0.001) 0.029
Trabecular separation (mm) 20 0.391 0.062 0.386 0.060 0.005 (−0.025 to 0.035) 0.732
Trabecular inhomogeneity 20 0.157 0.03 0.164 0.037 −0.007 (−0.025 to 0.011) 0.440
Stiffness (kN/mm) 20 195.3 27.9 207.5 37.1 −12.2 (−31.2 to 6.8) 0.194
Estimated failure load (kN) 20 10.04 1.35 10.66 1.83 −0.62 (−1.55 to 0.32) 0.185
(Tb.F/TF) distal (percentage of load carried by
trabecular bone at distal surface
20 72.4 12.3 77.6 8.1 −5.2 (−9.2 to −1.2) 0.013
(Tb.F/TF) proximal (percentage of load carried
by trabecular bone at proximal surface)
20 54.7 14.1 59.7 9.6 −5.0 (−9.8 to −0.1) 0.047
Trabecular Von Mises stress (MPa) 20 5.60 0.58 5.73 0.57 −0.13 (−0.41 to 0.15) 0.355
Cortical Von Mises stress (MPa) 20 8.09 0.68 8.02 0.55 0.07 (−0.17 to 0.31) 0.530
Significance is reached at p ≤ 0.05. BV/TV = bone volume fraction; N = number of matched pairs; mFEA = microfinite element analysis; T1DM = type 1
diabetes mellitus; Tb.F/TF = ratio of the load taken by the trabecular bone in relation to the total load.
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ex-vivo bone strength analysis. However, FEA is a well-
recognized process in engineering to assess material properties;
our results thus provide insight into the potential impact of
T1DMon skeletal strength. The rate of fractures in our population
is higher than reported in previous studies(41); this may have
resulted from an unconscious bias in families of participants
who volunteered to be part of the study. Finally, as HRpQCTmea-
sures bone strength and microstructure of the ultradistal radius
and tibia, we are unable to confirm whether the alterations
observed in adolescents with T1DM reflect changes in other
parts of the appendicular and axial skeleton. However, account-
ing for the limitations, we have found significant detrimental
changes in the trabecular microarchitecture and bone strength
proxies in adolescents with T1DM. Thus, we affirm our hypothe-
sis that detrimental changes in bonemicroarchitecture and prox-
ies in bone strength are seen in adolescents with T1DM, despite
no significant changes in DXA-derived bone mass.
Conclusion
T1DM is associated with a reduction in the trabecular thickness
in the tibia, and alterations in the loading properties at the ultra-
distal radius and tibia in adolescents with T1DM, despite there
being no significant reduction in BMD. Alterations in radial tra-
becular microarchitecture were seen in participants who have
had T1DM for at least 2 years, with no corresponding changes
in BMD. Poor glycemic control was associated with a reduction
in bone strength. Thus, in earlier life, bone microarchitecture
and strength, rather than bone density, may better explain the
increased risk of fracture observed in adults with T1DM.
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Cortical bone thickness (mm) 13 0.648 0.500 0.486 0.312 0.180 (−0.071 to 0.431) 0.144
Cortical bone perimeter (mm) 13 111.9 13.2 117.8 12.0 −5.8 (−14.0 to 2.3) 0.145
Cortical porosity 13 0.045 0.025 0.048 0.022 −0.004 (−0.019 to 0.012) 0.635
Trabecular bone area (cm3) 13 719.1 185.9 816.6 162.6 −97.5 (−213.7 to 18.64) 0.092
Trabecular bone density (mg/cm3) 13 177.3 23.0 190.6 23.5 −13.3 (−36.5 to 9.9) 0.235
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Inner trabecular density (mg/cm3) 13 146.8 22.5 160.2 25.9 −13.4 (−35.2 to 8.4) 0.206
Meta TB/inner TB 13 1.54 0.33 1.49 0.18 0.05 (−0.13 to 0.23) 0.588
Trabecular BV/TV 13 0.148 0.019 0.159 0.020 −0.011 (−0.030 to 0.008) 0.234
Trabecular bone number (1/mm) 13 2.15 0.23 2.06 0.37 0.10 (−0.13 to 0.32) 0.365
Trabecular thickness (mm) 13 0.069 0.010 0.076 0.009 −0.007 (−0.013 to −0.001) 0.029
Trabecular separation (mm) 13 0.402 0.046 0.405 0.058 −0.003 (−0.041 to 0.034) 0.861
Trabecular inhomogeneity 13 0.163 0.028 0.177 0.037 −0.014 (−0.038 to 0.010) 0.237
Stiffness (kN/mm) 13 194.3 27.7 205.3 40.3 −10.9 (−40.6 to 18.7) 0.437
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Periosteal perimeter (mm) 13 116.5 17.4 122.8 15.9 −6.3 (−16.0 to 3.3) 0.179
Endosteal perimeter (mm) 13 106.0 13.2 112.5 12.5 −6.5 (−14.5 to 1.6) 0.104
Significance is reached at p ≤ 0.05. BV/TV = bone volume fraction; N = number of matched pairs; mFEA = microfinite element analysis; T1DM = type 1 dia-
betes mellitus; TB = Meta TB/inner TB = meta-to-inner trabecular density; Tb.F/TF = ratio of the load taken by the trabecular bone in relation to the total load.
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